AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more
AMGN (AMGN) - Total Liabilities
Latest total liabilities as of December 2025: CA$81.93 Billion CAD
Based on the latest financial reports, AMGN (AMGN) has total liabilities worth CA$81.93 Billion CAD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AMGN - Total Liabilities Trend (2022–2025)
This chart illustrates how AMGN's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AMGN Competitors by Total Liabilities
The table below lists competitors of AMGN ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UDR Inc
NYSE:UDR
|
USA | $6.46 Billion |
|
Tenaga Nasional Bhd
KLSE:5347
|
Malaysia | RM147.24 Billion |
|
First Majestic Silver Corp
NYSE:AG
|
USA | $1.52 Billion |
|
Computershare Limited
PINK:CMSQF
|
USA | $2.86 Billion |
|
WFD Unibail Rodamco NV
PINK:UNBLF
|
USA | $27.99 Billion |
|
Smurfit Kappa Group Plc
PINK:SMFTF
|
USA | $27.42 Billion |
|
International Consolidated Airlines Group S.A.
PINK:BABWF
|
USA | $38.03 Billion |
|
China Minsheng Banking Corp. Ltd
F:GHFH
|
Germany | €7.07 Trillion |
Liability Composition Analysis (2022–2025)
This chart breaks down AMGN's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AMGN's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AMGN (2022–2025)
The table below shows the annual total liabilities of AMGN from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$81.93 Billion | -4.69% |
| 2024-12-31 | CA$85.96 Billion | -5.46% |
| 2023-12-31 | CA$90.92 Billion | +47.94% |
| 2022-12-31 | CA$61.46 Billion | -- |